Bristol Myers wins a big bet as their PhIII autoimmune drug beat out blockbuster Otezla — and that could cost Amgen dearly
Bristol Myers Squibb $BMY bet big on a Phase III psoriasis program for its TYK2 contender deucravacitinib (BMS-986165). And today they’re declaring their heavyweight contender the champ in a toe-to-toe bout with Amgen’s oral blockbuster Otezla, a must-win over a Celgene drug that Bristol Myers agreed to divest in order to complete the Celgene buyout.
Still missing from the first turn of Phase III cards are the actual hard data gleaned from the study, something that would automatically be lined up against rivals. But Bristol Myers execs are staking their rep on the claim that they scored statistically significant and clinically meaningful pivotal data that demonstrate a win on the primary endpoint on PASI 75 skin clearance for moderate to severe patients, with a secondary win on supremacy over Otezla.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,600+ biopharma pros reading Endpoints daily — and it's free.